Member Info for Dunnieboy

Aston Martin shareholders opposed the firm’s pay and its charman’s re-election.
Madness Stroll saves the co and 17% of investors want him out as chairman or a director.
Shareholders were also unhappy about Moers getting a £142,000 bonus as the car maker took government support in the pandemic.
Absolutely ridiculous for one, how would you prise Moers away from Mercedes AMG which was hugely profitable, to debt ridden AM without a fantastic package, the man is ‘top drawer’ and has moved to a foreign country, he’s taken a huge risk for which he should be rewarded.
As for not having Stroll as even a director, the man has pumped millions of his own money in and surely it’s better to have him running the company.

The news channel have just reported that you are only covered 30% against Covid from the first jab, so between the first and second jab you are obviously still 70% at risk of Covid.
For these reasons as well as numerous other such as weak immune systems etc we still need antibodies, this is where Sotrovimab comes into play with 85% efficacy after one jab, and retains half of life cover as well.
GSK are about to mount a epic defence battle with vaccine and antibodies to fight off this and other viruses, remember GSK stated ‘it’s not about being the first to produce vaccines, it’s about being the best’.
Buy GSK but look at Vir Bio as well.

Saying about shareholders revolts over the bonus payments, in my view if they’ve earned it, pay it.

Alive & kicking thanks, sold out a large chunk of Aston Martin for no other reason than I went very heavily into VIR Biotechnology and am awaiting a decision for ‘emergency use authorisation’ for a antibody drug they have developed with Glaxo.
If it goes right I intend to switch back, before anyone accuses me of ramping I stated this late last year.
I’ll check out the FB page.

Brummer wrote; European Medicines Agency has started a rolling review of Glaxo/Vir Biotechnology antibody medicine Sotrovimab(VIR7831).
They report that the medicine has produced ‘dramatic results’ when treating covid19 and helps prevent hospitalisation and death.
He said it may be a lifesaver in more ways than one, saying it may also save Emma Walmsley for the vultures circling.
This treatment shouldn’t be confused with a vaccine this is a treatment, actual treatments are few and far between.
VIR Bio trades on the Nasdaq and Motley Fool recently wrote it has the potential to be a ten bagger, Wall St consensus predicts it will double in a year.
FTimes recently predicted it could be a blockbuster for VIR & Glaxo

I’m hopeful Glaxo update the market about its investment in VIR Biotech.
The companies have submitted a application for ‘emergency use authorisation’ for VIR7831 which is a antibody therapy that was found to have ‘profound efficacy’ in clinical trials, eua was submitted on March 26 and a decision is expected any day now, given its 85% efficacy it is virtually a ‘rubber stamp’ job.

Motley Fool article suggesting questioning whether VIR could make you a millionaire, Glaxo has a major stake, VIR is set to make stunning returns as its antibody drugs are due to roll out the pipeline.

https://www.stck.pro/news/VIR/12362368

https://finance.yahoo.com/news/glaxo-gsk-vir-biotech-covid-111411808.html
VIR trades on the Nasdaq

https://youtu.be/-_SWdAhd3mYGood article on Motley Fool debating which shares would get the bigger lift from the collaboration between VIR/Glaxo & Lilly.VIR has the bigger risk but offers the greater rewards based on the fact it’s the smaller company.

VIR & GSK are about to receive ‘emergency use authorisation’ for VIR7831, GSK have a 7/10% stake in VIR Biotechnology.
Dr Alexander Edwards, Associate Professor in Biomedical Technology, Reading School of Pharmacy, University of Reading, said:

The success of VIR-7831 is spectacular and this new medicine would complement vaccines and other new treatments to make major reductions to the terrible impact of COVID-19.

“This class of drug could be especially important for those people who are less protected by vaccines for example if their immune system is weakened (as recently discussed for some cancer patients) – we can supplement their own immunity with this “extra” antibody against the virus.

“One reason this is so exciting is that it may herald a “breakthrough” for this class of medicines – monoclonal antibody treatment of viral infection. Monoclonal antibody drugs provide ‘artificial immunity’ by manufacturing antibodies in a bioreactor.
In contrast vaccines trigger your body to make your own antibodies (and other immune responses). Monoclonal antibody drugs have been most widely used to treat cancer and autoimmunity, but have always had enormous potential to directly combat an infection.
If the headline 85% reduction in hospitalisation or death translates into widespread use, this will deliver on the great promise of monoclonal antibodies to treat infections

Glaxo/VIR/Lilly have released top line data from the Blaze 4 trial they were participating in using a combined therapy of VIR7831 & Bamlanivimab.Glaxo has a stake in VIR.

Any idea how long the authorisation takes?

Spikey, I’m advocating the use of both, ive had the AstraZeneca and even the confidence of having had it helps.
Obviously from a financial point I’m a GSK/VIR man, but we need variations of treatments to cover as many people as we can.

Vaccines are preventive, antibodies are reactive to people who have the virus, it’s ‘horses for courses’, so to speak.

AstraZeneca has under 80% efficacy, Glaxo/VIR 7831 85%.

Antibodies is definitely the way forward, GSK/VIR 7831 restrains half life efficacy once administered so also acts as a vaccine, EUA is imminent, it may not boost GSK’s share price by much due to the giant it is but there are ‘buy’ recommendations out on VIR to reach $135 once approved, VIR currently $53, that’s the play.

The Times article rates GSK as a hold.

Read the article in the Times, slightly critical of GSK overpaying for acquisitions, but mentions its investment in ViR Bio Tech as a bright spot.
GSK & VIR have a application in for their antibody treatment VIR7831 for ‘emergency use approval’, treatment has reached a astonishing 85% efficacy in trials, in fact the trials were that successful that is was agreed to halt them early and go for eua.
VIR trades on the Nasdaq and has also trials underway for Hepatitis B which has also been producing fantastic data, well worth looking at.

Almostdone, GSK was tipped in yesterday’s MOS, it’s not old news.

Alex Lawson, Stocks to Watch; GSK’s fortunes may be improving.